Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

By /
Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination Read More

Related Posts

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Review Your Cart
0
Add Coupon Code
Subtotal
Checkout